Blog _Blog The Jardé Law and Research Involving Human Subjects (RIPH): How Are Pharmaceutical Companies Affected? Read more » June 28, 2024 _Blog The Excellence of ATESSIA’s CMC: Your Partner in Technical and Regulatory Affairs Read more » June 13, 2024 _Blog The Post-Approval Change Management Protocol or “PACMP” Read more » June 13, 2024 _Blog What are Good Manufacturing Practices (GMP) ? Read more » May 29, 2024 _Blog What are CEPs ? Read more » April 29, 2024 _Blog What is the European Pharmacopeia ? Read more » April 29, 2024 _Blog What future for therapeutic cannabis in France? Read more » April 24, 2024 _Blog Poisonous Substances: What Use within the Pharmaceutical Industry? Read more » March 19, 2024 _Blog Therapeutic patient education versus learning programs: what is role for the pharmaceutical industry? Read more » March 7, 2024 _Blog What is the Requirement for Transparency of Conflicts of Interest with Healthcare Professionals in France? Read more » December 20, 2023 _Blog What are the mechanisms for early and compassionate access in France? Read more » November 28, 2023 _Blog What about the classification of Marketing Authorization variations? Read more » November 27, 2023 Page1 Page2 Page3 Page4
_Blog The Jardé Law and Research Involving Human Subjects (RIPH): How Are Pharmaceutical Companies Affected? Read more » June 28, 2024
_Blog The Excellence of ATESSIA’s CMC: Your Partner in Technical and Regulatory Affairs Read more » June 13, 2024
_Blog Therapeutic patient education versus learning programs: what is role for the pharmaceutical industry? Read more » March 7, 2024
_Blog What is the Requirement for Transparency of Conflicts of Interest with Healthcare Professionals in France? Read more » December 20, 2023
_Blog What are the mechanisms for early and compassionate access in France? Read more » November 28, 2023
_Blog What about the classification of Marketing Authorization variations? Read more » November 27, 2023
